Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI, Inc. TEM is rapidly expanding its partnerships across oncology and neuroscience, leveraging its AI platforms — Lens and Next — to accelerate precision medicine. Tempus has entered into a ...

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects. Click here to read why TEM is a Hold.

Tempus Ai (NASDAQ: TEM) stock is seeing an explosive valuation surge in Tuesday's trading thanks to a pair of catalysts. The healthcare software company's share price was up 35.8% as of 3:15 p.m ...

Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn ...

The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them.